Pfizer will pay $11.6 billion for Biohaven

Pfizer said it will pay $11.6 billion to buy Biohaven Pharmaceutical Holding, betting big on its ability to boost sales of the top-selling pill in a new class of migraine drugs. Shares of Biohaven jumped 70% to $141.31, while shares of Pfizer rose slightly to $48.83.

Share this post:

Share on facebook
Share on twitter
Share on pinterest
Share on whatsapp
Related Posts
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore
WordPress Cookie Plugin by Real Cookie Banner